ArticleBMC infectious diseases2025
From decline to rebound: a 25-year Joinpoint analysis of tuberculosis mortality in the United States, 1999-2023.
Article in BMC infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundFollowing decades of consistent decline, tuberculosis (TB) mortality in the United States has exhibited indicators of stagnation since 2014. National-level summaries, however, conceal variability within demographic and geographic subgroups. Our objective was to quantify current trends and identify the demographics responsible for the deceleration.
methodsUtilizing the Centers for Disease Control and Prevention Wide-Ranging Online Data for Epidemiologic Research (CDC WONDER) mortality data (1999–2023), we computed age-adjusted mortality rates (AAMR) for all fatalities with underlying ICD-10 codes A16–A19. Joinpoint regression was utilized to calculate annual percent changes (APC) and average annual percent changes (AAPC) overall and stratified by sex, age, race/ethnicity, census area, and urbanization.
resultsTuberculosis-related fatalities decreased from 911 in 1999 to 566 in 2023, resulting in an overall annual average percentage reduction of −3.36% (95% CI −4.55% to −2.15%). In 2014, the national trend flipped; the APC transitioned from −5.86% (1999–2014) to +1.64% (2014–2023). Males encountered a more pronounced deceleration (APC −0.75% post-2011) compared to females. Adults aged 45–54 years experienced a fall of 5.01% per annum until 2017, followed by an increase of 3.71% per annum until 2023. Comparable reversals transpired in the 65–74 age cohorts, while individuals aged 85 and above had a consistent linear fall (APC −3.91%). The South and Northeast demonstrated the most pronounced reversals post-2015, with annual percentage changes of +1.98% and +3.03%, respectively. Metropolitan counties had a resurgence post-2015, with an increase of 2.69%, while non-metropolitan regions stabilized. Non-Hispanic Black adults experienced the most significant early drop (APC −9.12%, 1999–2013) and Non-Hispanic Asian adults continued to represent the largest burden group in 2023.
conclusionsU.S. tuberculosis mortality has shifted from a rapid drop to stagnation or resurgence, particularly evident among middle-aged and older adults, males, urban inhabitants, and those in Southern and Northeastern states. Urgent, equity-centered actions are essential to avert further recurrence and expedite elimination.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.